Showing posts with label development. Show all posts
Showing posts with label development. Show all posts

Monday, 31 October 2011

Biologists describe key mechanism in early embryo development

AppId is over the quota
AppId is over the quota
ScienceDaily (Oct. 20, 2011) — New York University and University of Iowa biologists have identified a key mechanism controlling early embryonic development that is critical in determining how structures such as appendages -- arms and legs in humans -- grow in the right place and at the right time.

In a paper published in the journal PLoS Genetics, John Manak, an assistant professor of biology in the UI College of Liberal Arts and Sciences, and Chris Rushlow, a professor in NYU's Department of Biology, write that much research has focused on the spatial regulatory networks that control early developmental processes. However, they note, less attention has been paid to how such networks can be precisely coordinated over time.

Rushlow and Manak find that a protein called Zelda is responsible for turning on groups of genes essential to development in an exquisitely coordinated fashion.

"Zelda does more than initiate gene networks -- it orchestrates their activities so that the embryo undergoes developmental processes in a robust manner at the proper time and in the correct order," says Rushlow, part of NYU's Center for Developmental Genetics.

"Our results demonstrate the significance of a timing mechanism in coordinating regulatory gene networks during early development, and bring a new perspective to classical concepts of how spatial regulation can be achieved," says Manak, who is also assistant professor of pediatrics in the Roy J. and Lucille A. Carver College of Medicine and researcher in the UI Roy J. Carver Center for Genomics.

The researchers note that their findings break new ground.

"We discovered a key transcriptional regulator, Zelda, which is the long-sought-after factor that activates the early zygotic genome," says Rushlow.

"Initially, the embryo relies on maternally deposited gene products to begin developing, and the transition to dependence on its own zygotic genome is called the maternal-to-zygotic transition," she adds. "Two hallmark events that occur during this transition are zygotic gene transcription and maternal RNA degradation, and interestingly, Zelda appears to be involved in both processes."

The research showed that when Zelda was absent, activation of genes was delayed, thus interfering with the proper order of gene interactions and ultimately disrupting gene expression patterns, the researchers noted, adding that the consequence to the embryo of altered expression patterns is a drastic change in the body plan such that many tissues and organs are not formed properly, if at all.

The researchers used Drosophila, or fruit flies, to investigate these regulatory networks. The fruit fly has the advantage of being a tractable genetic model system with a rapid developmental time, and many of the genetic processes identified in flies are conserved in humans. Additionally, pioneering fly research has led to many of the key discoveries of the molecular mechanisms underlying developmental processes in complex animals.

The study brought together Rushlow, who discovered Zelda and is an expert in genetic regulatory networks in development, and Manak, a genomics expert whose laboratory focuses on how a genome is constructed and coordinately functions.

"I had always wanted to work with Chris, and this was a wonderful opportunity for us to combine our complementary areas of expertise in a truly synergistic fashion," says Manak.

"Our collaboration is a marvelous example of how a problem can be viewed from two different perspectives, a systems view of early gene networks and an individualistic view of single genes and single embryos, and result in novel and significant discoveries," says Rushlow.

The project's other researchers were: Stephen Butcher of the UI Departments of Pediatrics and Biology; and Chung-yi Nien, Hsiao-lan Liang, Yujia Sun, Shengbo Fu, Tenzin Gocha, and Nikolai Kirov, all of the Center for Developmental Genetics, part of NYU's Department of Biology.

The research was funded by grants from the National Institutes of Health.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by New York University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Chung-Yi Nien, Hsiao-Lan Liang, Stephen Butcher, Yujia Sun, Shengbo Fu, Tenzin Gocha, Nikolai Kirov, J. Robert Manak, Christine Rushlow. Temporal Coordination of Gene Networks by Zelda in the Early Drosophila Embryo. PLoS Genetics, 2011; 7 (10): e1002339 DOI: 10.1371/journal.pgen.1002339

Note: If no author is given, the source is cited instead.

Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Saturday, 29 October 2011

Coupling of proteins promotes glioblastoma development, researchers find

AppId is over the quota
AppId is over the quota
ScienceDaily (Oct. 21, 2011) — Two previously unassociated proteins known to be overly active in a variety of cancers bind together to ignite and sustain malignant brain tumors, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports this week in the journal Cancer Cell.

This research is the first to connect FoxM1 to a molecular signaling cascade that regulates normal neural stem cells, said senior author, Suyun Huang, M.D., Ph.D., associate professor in MD Anderson's Department of Neurosurgery.

"When FoxM1 binds to beta-catenin, we found that it also supports the self-renewal and differentiation of glioma-initiating cells, cancer stem cells thought to drive glioblastoma multiforme," Huang said.

Glioblastoma multiforme is the most common and lethal form of brain tumor. Glioma-initiating cells are prime suspects in the disease's resistance to treatment and ability to reoccur.

Protein's connection could be drug target

The scientists established the relationship between FoxM1 and beta-catenin in a series of cell line experiments and then confirmed their findings in mouse models of human glioblastoma and in an analysis of human tumors.

FoxM1 and beta-catenin separately so far have largely evaded targeting by drugs. Huang and her team are focusing on the details of the connection between the two proteins in search of small molecules that might block their binding.

"Our study might lead to the development of a new class of small-molecule anti-cancer drugs, including but not necessarily limited to glioblastoma multiforme," Huang said. Much preclinical work remains before such a drug can be identified and brought to clinical trial.

Blocking FoxM1 reduces glioblastoma in mice 100 percent

FoxM1 previously was known solely as a transcription factor -- a protein that binds to the DNA in a gene's promoter region to prompt the gene's expression of messenger RNA that is processed into a protein.

Structural analysis led Huang and her team to suspect FoxM1 might be a binding match for beta-catenin, a crucial protein in the Wnt signaling pathway, which regulates self-renewal and differentiation of neural stem cells. When a normal cell divides, it produces two copies of itself. A neural stem cell produces one copy of itself (self-renewal) and a copy of a functional brain cell, such as a neuron or an astrocyte (differentiation). Mutations occur in the Wnt pathway in other types of cancer, but are largely absent in glioblastoma.

Blocking either FoxM1 or beta-catenin function strongly influenced whether mice injected with glioblastoma cells developed brain tumors. Most dramatically, blocking FoxM1 with short hairpin RNA completely prevented development of brain tumors in 38 mice, while all 20 with unimpeded FoxM1 developed tumors.

In a series of cell line experiments leading to the mouse model research, the group found:

FoxM1 is expressed at high levels in glioma and in glioma-initiating cells.FoxM1 and beta-catenin bind to each other in tumor cells.Wnt promotes the movement of both FoxM1 and beta-catenin to the cell nucleus.FoxM1 is required for beta-catenin to move to the cell nucleus in both neural stem cells and in tumor cells.The FoxM1 and beta-catenin connection is required for transcription and expression of beta-catenin Wnt-targeted genes in the nucleus.Interaction between the two proteins is critical to both cell renewal and differentiation in glioma stem cells.

The team analyzed 40 glioblastoma samples and found FoxM1 moderately expressed in 14 and highly expressed in 18. Levels of FoxM1 in the cell nucleus correlated directly with levels of beta-catenin expression and the expression of two Wnt target genes.

Additional analysis of eight tumors found the two proteins present together in the cell nuclei and a direct correlation with the presence of one protein marker for glioma-initiating cells.

Co-authors with Huang are first authors Nu Zhang, Ph.D., and Ping Wei, Ph.D., Aihua Gong, Ph.D., Wen-Tai Chiu, Ph.D, Hsueh-Te Lee, Ph. D, Jianfei Xue, Ph.D., Mingguang Liu, M.D., Yong Wang, Ph.D., and Raymond Sawaya, M.D. ,of MD Anderson's Department of Neurosurgery; Howard Colman, M.D., and W.K. Alfred Yung, M.D., of MD Anderson's Department of Neuro-Oncology. Keping Xie, M.D., Ph.D .,of MD Anderson's Department of Gastrointestinal Medical Oncology and the program in cancer biology at The University of Texas Graduate School of Biomedical Science at Houston; Rene Medema, M.D., of the Department of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands; and Xi He, Ph.D., and He Huang, Ph.D., of the F.M. Kirby Neurobiology Center, Children's Hospital Boston and Harvard Medical School.

Artwork chosen by Cell Press for the cover of Cancer Cell was designed by Huang's daughter Victoria Xie, a sophomore at Michael DeBakey High School for Health Professions in Houston.

This research was funded by grants from the National Cancer Institute, the National Institute of General Medical Sciences, a multidisciplinary research grant by MD Anderson, and the Leukemia and Lymphoma Society.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Texas M. D. Anderson Cancer Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Nu Zhang, Ping Wei, Aihua Gong, Wen-Tai Chiu, Hsueh-Te Lee, Howard Colman, He Huang, Jianfei Xue, Mingguang Liu, Yong Wang, Raymond Sawaya, Keping Xie, W.K. Alfred Yung, René H. Medema, Xi He, Suyun Huang. FoxM1 Promotes ß-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis. Cancer Cell, 2011; 20 (4): 427 DOI: 10.1016/j.ccr.2011.08.016

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Monday, 24 October 2011

Research involving thyroid hormone lays foundation for more targeted drug development

AppId is over the quota
AppId is over the quota
ScienceDaily (Oct. 21, 2011) — Research led by St. Jude Children's Research Hospital scientists advances a strategy for taming the side effects and enhancing the therapeutic benefits of steroids and other medications that work by disrupting the activity of certain hormones.

The approach relies on a small molecule developed at St. Jude. In this study, scientists showed that a compound known as SJ-AK selectively blocked the activity of genes in a cell signaling pathway regulated by thyroid hormone.

Investigators showed that SJ-AK also affected cells growing in the laboratory, reducing cell proliferation as well as the production and secretion of a growth hormone regulated by thyroid hormone. The research appears in the October issue of the scientific journal ACS Chemical Biology.

The findings raise hope that compounds like SJ-AK will lead to drugs with more tailored effects by selectively controlling signaling pathways that switch genes on and off. This research focused on a pathway controlled by a thyroid hormone. Investigators said, however, the approach also could potentially be used to target pathways regulated by glucocorticoid, estrogen, androgen and other hormones that are widely used to treat cancer and other conditions but that also have serious side effects.

"This study offers the first evidence it is possible to shut down a portion of the signaling network activated by a particular hormone," said R. Kiplin Guy, Ph.D., chair of the St. Jude Chemical Biology and Therapeutics Department. Guy is the senior author. The first author is Prabodh Sadana, Ph.D., a former St. Jude postdoctoral fellow who now works in the Department of Pharmaceutical Sciences at Northeastern Ohio Universities College of Medicine and Pharmacy.

Such selectivity could lead to a new generation of medications that promise greater effectiveness and fewer side effects. The new treatments could include steroids that fight leukemia or suppress the inflammation associated with autoimmune disorders without affecting metabolism or bone strength. Small molecules like SJ-AK might aid efforts to develop medicines to control the rapid, life-threatening over-production of a thyroid hormone known as thyroid storm. Guy said the thyroid hormone pathway is also being studied for new opportunities to better regulate obesity or metabolic disease related to cholesterol, triglycerides and fatty acids.

For this study, researchers compared the activity of SJ-AK and NH-3. The compounds use different techniques to target distinct spots in a thyroid hormone signaling pathway.

NH-3 works by competing with a thyroid hormone to bind to the receptor in the cell nucleus. If the hormone wins the competition, the binding starts a biochemical cascade that regulates the activity of genes in the pathway. Those genes produce the proteins that affect growth and other key biological processes. If NH-3 binds to the receptor instead, the impact is like flipping the switch that cuts electricity to the entire building. The entire pathway remains dormant, which is not always desirable.

SJ-AK was developed in Guy's laboratory. Rather than binding to the hormone receptor like NH-3 does, SJ-AK targets the next step in the pathway. SJ-AK works by displacing proteins called coactivators. Coactivator proteins normally bind to a pocket that is created when a thyroid hormone and receptor bind. As a result, SJ-AK functions like a circuit breaker, selectively blocking parts of the hormone signaling pathway.

In this study, researchers showed that while NH-3 and SJ-AK both target the same signaling pathway and some of the same genes, SJ-AK affects far fewer genes. In laboratory screening tests, researchers found the activity of 193 genes was affected by thyroid hormone. The genes included 79 whose activity was affected by NH-3 and 28 affected by SJ-AK. Investigators showed NH-3 and SJ-AK had little impact on genes outside the thyroid hormone pathways.

Scientists showed NH-3 and SJ-AK also altered the activity of cells. Growth hormone secretion increased 50 percent following the addition of thyroid hormone to human cells growing in the laboratory. When SJ-AK was added, the secretion of growth hormone fell. In another laboratory experiment, researchers reported that both NH-3 and SJ-AK blocked the cell proliferation triggered by growth hormone secretion.

Other authors are Jong Yeon Hwang and Ramy Attia, both formerly of St. Jude; Geoffrey Neale, of St. Jude; and Leggy Arnold of the University of Wisconsin at Milwaukee.

This research was funded in part by the National Institutes of Health and ALSAC.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by St. Jude Children's Research Hospital.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Prabodh Sadana, Jong Yeon Hwang, Ramy R. Attia, Leggy A. Arnold, Geoffrey Neale, R. Kiplin Guy. Similarities and Differences between Two Modes of Antagonism of the Thyroid Hormone Receptor. ACS Chemical Biology, 2011; 6 (10): 1096 DOI: 10.1021/cb200092v

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here